Paul Hastings Advised Keensight Capital in the Acquisition of Inke
Paul Hastings (Europe) LLP advised Keensight Capital in connection with the acquisition of Inke, a specialized inhalation active pharmaceutical ingredients (APIs) developer and manufacturer, previously owned by the Neuraxpharm Group.
Corporate partner Olivier Deren led the Paul Hastings team, which also included associate Vincent Nacinovic on contractual and corporate aspects, as well as partner Allard de Waal on the tax aspects.
More details on the transactions can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.